Login to Your Account



Encysive Stock Moves Up 12 Percent On Thelin Data

By Karen Pihl-Carey


Tuesday, February 15, 2005
Encysive Pharmaceuticals Inc. plans to file a new drug application in April based on pivotal Phase III data showing that Thelin met its primary endpoint in pulmonary arterial hypertension. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription